This bill would require a REMS-certified provider to prescribe mifepristone only after an in-person visit and only if the provider holds a medical license in the state where the patient lives. In practice, it would narrow access to medication abortion and other uses of mifepristone by making cross-state telehealth prescribing harder. The main people affected would be patients seeking the drug, abortion and reproductive health providers, and pharmacies that dispense it. The bill does not specify a new federal payment or subsidy amount; instead, it changes the conditions under which the drug can be prescribed.
What This Bill Does
- Requires an in-person visit before mifepristone can be prescribed.
- Limits prescribing to a provider licensed in the patient’s state.
- Applies to REMS-certified providers under the federal safety program.
- Would mainly affect patients seeking medication abortion and clinicians who prescribe it.
Who This Bill Affects
If you are a patient who might seek mifepristone, this bill would likely mean needing an in-person appointment and a prescriber licensed in your home state, which could add travel time, scheduling delays, and out-of-pocket costs. If you are a provider, especially one serving patients across state lines by telehealth, it would narrow where and how you can prescribe the drug. For the general public, the bill would mainly matter through its effect on access to medication abortion and related reproductive health care.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- abortion opponents They would argue the bill adds a direct doctor-patient exam before a high-stakes medication is prescribed and gives states clearer control over how the drug is used. They may see the licensing requirement as a way to prevent remote prescribing from bypassing local medical standards.
- state medical regulators They may support a state-licensure rule because it makes enforcement simpler and keeps prescribing authority tied to the state where the patient is located. That can be framed as improving accountability if something goes wrong.
- some clinicians concerned about oversight Some physicians may argue that an in-person visit can help confirm eligibility, review risks, and document consent. They may view the requirement as a safeguard for patient safety, especially in cases where follow-up could be difficult.
- reproductive health patients Patients would likely argue that the bill forces unnecessary travel and delays, especially for people in rural areas or states with few clinics. For many, telehealth is the difference between timely care and missing the window for medication abortion.
- abortion providers and telehealth clinicians They would likely say the bill overrides established telemedicine models and creates a patchwork of state-by-state restrictions that are difficult to administer. The licensure rule could block care even when a clinician is fully qualified and working within the REMS framework.
- patient access and public health advocates They may argue that the bill raises costs without adding meaningful benefit for most patients who are already screened remotely and counseled on warning signs. In their view, the main effect would be reduced access rather than better care.
Key Implications
-
““without an in-person visit””
This would bar remote-only prescribing and require a physical appointment before the medication can be dispensed. Patients who depend on telehealth would need to travel in person, which can add time, cost, and delay.
-
““a medical license in the State in which the patient resides””
The prescriber would need to be authorized to practice in the patient’s state, not just in their own. That could limit cross-state telemedicine and reduce the number of clinicians able to serve patients living in restrictive or underserved states.
-
““REMS-certified provider””
The requirement would apply within the federal risk-evaluation and mitigation framework for mifepristone. In real terms, it targets the special prescribing rules already attached to the drug rather than creating a brand-new drug approval process.
-
““for other purposes””
This phrase signals the bill may include additional related changes beyond the core prescription restrictions. Any such changes would likely be aimed at tightening how the drug is prescribed, dispensed, or overseen.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- HR 9421
- Congress
- 119th Congress
- Official title
- To prohibit a REMS-certified provider from prescribing mifepristone without an in-person visit and a medical license in the State in which the patient resides, and for other purposes.
- Policy area
- Healthcare
- Latest action
- Referred to the House Committee on Energy and Commerce. (June 24, 2026)
- Last updated
- June 25, 2026
Latest Status
June 24, 2026
Referred to the House Committee on Energy and Commerce.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.